Andrew Sochacki
Affiliations: | 2015-2020 | Department of Medicine | Vanderbilt University, Nashville, TN |
Google:
"Andrew Sochacki"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mack T, Vlasschaert C, von Beck K, et al. (2024) Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamics. The Journal of Molecular Diagnostics : Jmd |
| Kishtagari A, Khan MAW, Li Y, et al. (2024) Driver mutation zygosity is a critical factor in predicting clonal hematopoiesis transformation risk. Blood Cancer Journal. 14: 6 |
| Mack T, Vlasschaert C, von Beck K, et al. (2023) Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamics. Medrxiv : the Preprint Server For Health Sciences |
| Sochacki AL, Bejan CA, Zhao S, et al. (2022) Patient-specific comorbidities as prognostic variables for survival in myelofibrosis. Blood Advances |
| Moyo TK, Watts JM, Skikne BS, et al. (2019) Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition Blood. 134: 4236-4236 |
| Sochacki A, Zhao S, Bejan CA, et al. (2019) JAK2V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts. Blood. 134: 1203-1203 |
| Bose P, Nazha A, Komrokji RS, et al. (2018) Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood |
| Sochacki A, Bejan CA, Zhao S, et al. (2018) Next Generation Myelofibrosis Risk Analysis in the Electronic Health Record Blood. 132: 3038-3038 |
| Sochacki AL, Fischer MA, Savona MR. (2016) Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. Oncotargets and Therapy. 9: 2273-86 |
| Sochacki AL, Fischer MA, Savona MR. (2016) Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Oncotargets and Therapy. 9: 2273-2286 |